Entry
Name
Dapsone (USP); Diaphenylsulfone (JAN); Aczone (TN)
Product
Generic
DAPSONE (ANI Pharmaceuticals) ,
DAPSONE (Alembic Pharmaceuticals) ,
DAPSONE (Amneal Pharmaceuticals LLC) ,
DAPSONE (Amneal Pharmaceuticals NY LLC) ,
DAPSONE (Aphena Pharma Solutions - Tennessee) ,
DAPSONE (AvKARE) ,
DAPSONE (Cosette Pharmaceuticals) ,
DAPSONE (Coupler LLC) ,
DAPSONE (Encube Ethicals Private Limited) ,
DAPSONE (Golden State Medical Supply) ,
DAPSONE (Jacobus Pharmaceutical Company) ,
DAPSONE (Mayne Pharma Commercial LLC) ,
DAPSONE (Mayne Pharma) ,
DAPSONE (Mylan Pharmaceuticals) ,
DAPSONE (NORTHSTAR RX LLC) ,
DAPSONE (NORTHSTAR RX LLC) ,
DAPSONE (Nostrum Laboratories) ,
DAPSONE (Pacific Pharma) ,
DAPSONE (Proficient Rx LP) ,
DAPSONE (Rising Pharma Holdings) ,
DAPSONE (Taro Pharmaceuticals U.S.A.) ,
DAPSONE (Taro Pharmaceuticals U.S.A.) ,
DAPSONE (Taro Pharmaceuticals U.S.A.) ,
DAPSONE (Torrent Pharmaceuticals Limited) ,
DAPSONE (Trupharma) ,
DAPSONE (Trupharma) ,
DAPSONE (Viona Pharmaceuticals) ,
DAPSONE (Westminster Pharmaceuticals) ,
DAPSONE (Zydus Lifesciences Limited) ,
DAPSONE TABLETS (Everest Life Sciences. LLC)
Formula
C12H12N2O2S
Exact mass
248.0619
Mol weight
248.30
Structure
Mol file KCF file DB search
Simcomp
Neighbor
Class
Metabolizing enzyme substrate
DG02855 CYP2E1 substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
Remark
Efficacy
Antibacterial (leprostatic)
Disease
Comment
Diaminodiphenylsulfone derivative
Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency [DS:
H00668 ] are more prone to hemolysis with the use of Dapsone.
Suppression of dermatitis herpetiformis
Target
dihydropteroate synthase [KO:
K00796 ]
Pathway
Metabolism
Enzyme: CYP2E1 [HSA:
1571 ], CYP3A4 [HSA:
1576 ]
Interaction
DDI search
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303 ]
D DERMATOLOGICALS
D10 ANTI-ACNE PREPARATIONS
D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE
D10AX Other anti-acne preparations for topical use
D10AX05 Dapsone
D00592 Dapsone (USP) <JP/US>
J ANTIINFECTIVES FOR SYSTEMIC USE
J04 ANTIMYCOBACTERIALS
J04B DRUGS FOR TREATMENT OF LEPRA
J04BA Drugs for treatment of lepra
J04BA02 Dapsone
D00592 Dapsone (USP) <JP/US>
USP drug classification [BR:br08302 ]
Antimycobacterials
Antimycobacterials, Other
Dapsone
D00592 Dapsone (USP)
Dermatological Agents
Topical Anti-infectives
Antibacterials, Dermatological
Dapsone
D00592 Dapsone (USP)
Therapeutic category of drugs in Japan [BR:br08301 ]
2 Agents affecting individual organs
26 Epidermides
269 Miscellaneous
2699 Others
D00592 Dapsone (USP); Diaphenylsulfone (JAN)
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
623 Leprostatics
6231 Sulfones
D00592 Dapsone (USP); Diaphenylsulfone (JAN)
Drug groups [BR:br08330 ]
Metabolizing enzyme substrate
DG02855 CYP2E1 substrate
D00592 Dapsone
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D00592 Dapsone
Antimicrobials [BR:br08307 ]
Antibacterials
Folic acid biosynthesis inhibitor
Diaminodiphenyl sulfone
D00592 Dapsone (USP) <JP/US>
Drug metabolizing enzymes and transporters [br08309.html ]
Drug metabolizing enzymes
D00592
Pharmacogenomic biomarkers [br08341.html ]
Polymorphisms and mutations affecting drug response
D00592
Prodrugs [br08324.html ]
D00592
BRITE hierarchy
Other DBs
LinkDB
All DBs
KCF data
Show ATOM 17
1 S4a S 21.9800 -14.6136
2 C8y C 23.1922 -15.3246
3 C8y C 20.7736 -15.3187
4 O3c O 20.9776 -13.6228
5 O3c O 22.9708 -13.6228
6 C8x C 24.4045 -14.6195
7 C8x C 23.1922 -16.7234
8 C8x C 19.5614 -14.6136
9 C8x C 20.7736 -16.7175
10 C8x C 25.6050 -15.3187
11 C8x C 24.4045 -17.4168
12 C8x C 18.3433 -15.3187
13 C8x C 19.5614 -17.4168
14 C8y C 25.6167 -16.7234
15 C8y C 18.3433 -16.7175
16 N1a N 26.8174 -17.4285
17 N1a N 17.1369 -17.4168
BOND 18
1 1 2 1
2 1 3 1
3 1 4 2
4 1 5 2
5 2 6 2
6 2 7 1
7 3 8 2
8 3 9 1
9 6 10 1
10 7 11 2
11 8 12 1
12 9 13 2
13 10 14 2
14 12 15 2
15 14 16 1
16 15 17 1
17 11 14 1
18 13 15 1